View Older Stories View More Recent Stories
-
A New Era in Schizophrenia Care: National Council for Mental Wellbeing and Bristol Myers Squibb Collaborate to Advance Evidence-Based Care Models
-
insitro expands Bristol Myers Squibb partnership with two new ALS targets
-
Bristol Myers Squibb wins FDA and EU approvals for Opdivo in Hodgkin lymphoma
-
RBC Capital on Biopharma: 'M&A Discussion, Whether Accurate Or Not, Can Drive Returns'
-
Bristol-Myers Squibb Co. (BMY) PT Raised to $70 at Jefferies: SUCCESSOR-2 interim validates CELMoD strategy
-
Raymond James looks for further durability in BMY's (BMY) MountainTAP-30 trial
-
Bristol-Myers Squibb Co. (BMY) PT Raised to $70 at UBS Ahead of Major Catalyst
-
Bristol-Myers Squibb (BMY) Declares $0.63 Quarterly Dividend; 4% Yield
-
Stifel Earlier Defended Tango Therapeutics Inc. (TNGX) Amid 12pct Decline
-
Iza-bren meets dual endpoints in phase III breast cancer trial
-
RBC Capital Starts Bristol-Myers Squibb Co. (BMY) at Sector Perform
-
Bristol-Myers Squibb Co. (BMY) PT Raised to $75 at Piper Sandler
-
Barclays Starts Bristol-Myers Squibb Co. (BMY) at Overweight
-
FDA accepts Bristol Myers Squibb drug application for multiple myeloma
-
Bristol-Myers Squibb receives orphan drug designation for lymphoma treatment
-
Bernstein Weighs In on Bristol-Myers Squibb (BMY) Ahead of H2 Critical Clinical Readouts
-
Bristol-Myers Squibb Co. (BMY) PT Raised to $72 at Guggenheim
-
Bristol-Myers Squibb Co. (BMY) PT Raised to $60 at Wells Fargo
-
Truist: 'We remain incrementally positive on BMY'
-
Bristol-Myers Squibb (BMY) Tops Q4 EPS by 14c, Beats on Revenue; Offers FY26 Guidance
-
Stocks expected to have increasing option volume: BMY KKR CMI CI CBOE CARR CAH EL HSY TPR RL PTON AMZN MSTR BIIB ALGT MOD M KLIC HP
-
Bristol Myers Squibb partners with Kasey Keller on lymphoma awareness
-
Bristol-Myers Squibb (BMY) call put ratio 1.6 calls to 1 put into quarter results
-
Bristol Myers Squibb launches educational campaign on cardiovascular care
-
Bristol-Myers Squibb Co. (BMY) PT Raised to $66 at Piper Sandler
-
Bristol Myers Squibb partners with Microsoft on lung cancer AI detection
-
Bristol Myers Squibb Announces Collaboration with Microsoft to Advance AI-Driven Early Detection of Lung Cancer
-
Bristol Myers Squibb partners with Microsoft on AI lung cancer detection
-
Bristol-Myers Squibb Co. (BMY) PT Raised to $60 at Leerink Partners
-
Bristol-Myers Squibb Co. (BMY) PT Raised to $60 at Scotiabank
-
Bristol-Myers Squibb (BMY) call put ratio 1.5 calls to 1 put into the annual J.P. Morgan Healthcare Conference
-
UBS Assumes and Upgrades Bristol-Myers Squibb Co. (BMY) at Buy
-
Guggenheim Reiterates Buy Rating on Bristol-Myers Squibb Co. (BMY)
-
Bristol Myers Squibb strikes deal with US government on drug pricing
-
14 of 17 Leading Drug Manufactures Now Part of Trump Most Favored Nation Efforts
-
Bristol Myers receives FDA orphan drug designation for systemic sclerosis
-
BofA Securities Upgrades Bristol-Myers Squibb Co. (BMY) to Buy
-
Guggenheim Upgrades Bristol-Myers Squibb Co. (BMY) to Buy
-
Bristol-Myers Squibb (BMY) Raises Quarterly Dividend 1.6% to $0.63; 4.9% Yield
-
Bristol Myers Squibb presents lymphoma research data at ASH 2025
-
FDA approves Bristol Myers Squibb Breyanzi for marginal zone lymphoma
-
Bristol-Myers Squibb Co. (BMY) PT Raised to $53 at Scotiabank
-
Truist Securities on Bristol-Myers Squibb Co. (BMY): 'overall positive'
-
Bristol Myers Squibb presents hematology pipeline data at ASH 2025
-
Bernstein on IRA pricing: $245 really is the floor
-
Guggenheim Reiterates Neutral Rating on Bristol-Myers Squibb Co. (BMY)
-
Bristol-Myers Squibb (BMY) call put ratio1.7 calls to 1 put amid price movement
-
Bristol Myers Squibb gains European approval for Breyanzi in mantle cell lymphoma
-
Bristol-Myers Squibb's (BMY) Milvexian Can Reset Sentiment - Cantor Fitzgerald
-
Bristol-Myers Squibb's (BMY) Milvexian Can Reset Sentiment Positively - Cantor Fitzgerald
